Please login to the form below

Not currently logged in
Email:
Password:

Takeda will acquire Nycomed, reports say

Takeda Pharmaceutical Company has agreed to buy Swiss drugmaker Nycomed in a deal worth around 1trn yen ($12bn), according to a report in Japanese newspaper, Nikkei

Takeda Pharmaceutical Company has agreed to buy Swiss drugmaker Nycomed in a deal worth around 1trn yen ($12bn), according to a report in Japanese newspaper, Nikkei.

The report follows denials by Takeda, the largest pharma company in Japan, earlier this month: "Takeda has not agreed to any such agreement as suggested by certain newspaper publications… Takeda is constantly seeking and evaluating opportunities to increase shareholder value and enhance our business through strategic investment, however, there is nothing that needs to be announced at this point."

Initial media reports had alleged that the deal was in its final stages, while another said that Takeda is talking to banks about financing the deal.

Rumours of the deal came just days after Nycomed entered into a co-branding agreement with Almirall to commercialise roflumilast in Spain. Romflumilast is a once-daily tablet for patients with COPD. It is an orally administered phosphodiesterase 4 (PED4) enzyme inhibitor and the first oral anti-inflammatory treatment for COPD.

Related stories
Takeda denies Nycomed takeover talks
Almirall/Nycomed COPD co-branding deal

18th May 2011

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Viseven

Viseven is a Global MarTech Services Provider for Pharma and Life Sciences Industries...

Latest intelligence

Top-10 Reasons Why You Should be Adding Asynchronous Virtual Touchpoints Between Your Real-time Meetings
...
Flu
Influenza – the risk to vulnerable populations
Why we can't get complacent about flu vaccination...
dementia
Alzheimer’s Research UK highlights socio-economic inequalities in dementia risk
The charity aims to improve the number of women participating in dementia research and grow awareness of dementia risk factors...